Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide,a highly potent,selective, and orally efficacious factor Xa inhibitor |
| |
Authors: | Penglie Zhang Wenrong Huang Lingyan Wang Liang Bao Zhaozhong J Jia Shawn M Bauer Erick A Goldman Gary D Probst Yonghong Song Ting Su Jingmei Fan Yanhong Wu Wenhao Li John Woolfrey Uma Sinha Paul W Wong Susan T Edwards Ann E Arfsten Lane A Clizbe James Kanter Bing-Yan Zhu |
| |
Institution: | Millennium Pharmaceuticals, Inc., 256 East Grand Avenue, South San Francisco, CA 94080, USA |
| |
Abstract: | Systematic SAR studies of in vitro factor Xa inhibitory activity around compound 1 were performed by modifying each of the three phenyl rings. A class of highly potent, selective, efficacious and orally bioavailable direct factor Xa inhibitors was discovered. These compounds were screened in hERG binding assays to examine the effects of substitution groups on the hERG channel affinity. From the leading compounds, betrixaban (compound 11, PRT054021) has been selected as the clinical candidate for development. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|